Pharmacologic class: Histamine1 (H1)-receptor antagonist
Therapeutic class: Antihistamine
Pregnancy risk category B
Exerts principal antihistaminic effects via selective inhibition of H1 receptors
Oral solution: 2.5 mg/5 ml (0.5 mg/ml)
Tablets: 5 mg
⊘Indications and dosages
➣ Symptoms of allergic rhinitis (seasonal and perennial); uncomplicated skin manifestations of chronic idiopathic urticaria
Adults and children ages 12 and older: 5 mg P.O. daily in evening
Children ages 6 to 11: 2.5 mg P.O. daily in evening; don't exceed recommended dosage.
• Renal impairment.
• Hepatic impairment
• Hypersensitivity to drug, its components, or cetirizine
• End-stage renal disease
• Renal impairment (children ages 6 to 11)
Use cautiously in:
• renal impairment
• pregnant patients
• elderly patients
• breastfeeding patients (use not recommended)
• children younger than age 6 (safety and efficacy not established).
• Give with or without food.
CNS: somnolence, fatigue, asthenia
EENT: epistaxis (children), nasopharyngitis, pharyngitis
GI: dry mouth
Respiratory: cough (children)
Other: pyrexia (children)
Drug-drug.Ritonavir: increased levocetirizine blood level and half-life, decreased clearance
Drug-behaviors.Alcohol use: increased risk of impaired CNS function
• Stay alert for excessive CNS depression.
• Closely monitor renal function tests in patients with renal impairment.
• Tell patient drug can be taken with or without food.
• Instruct patient to avoid alcohol and other depressants, such as sleeping pills, unless prescriber approves.
• Caution patient to avoid hazardous activities until drug's effects on concentration and alertness are known.
• Advise female patient to notify prescriber if she is pregnant or intends to become pregnant.
• Tell breastfeeding patient to discontinue breastfeeding during therapy.
• As appropriate, review all other significant adverse reactions and interactions, especially those related to the drugs and behaviors mentioned above.